secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261689
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology Q3 net loss $22.0M; cash $77.7M, runway into H2 2026
-------------------------------------------------------------------

- Net loss $22.0M ($0.35/share) for Q3 2025, vs $21.2M loss in Q3 2024.
- Cash and equivalents $77.7M; expected to fund operations into H2 2026.
- R&D expenses $17.8M; increase in MICVO costs offset by pause of PYX-106 program.
- Preliminary Phase 1 data for micvotabart pelidotin (MICVO) in HNSCC expected in Q4 2025.
- Translational data presented at ESMO and AACR-NCI-EORTC on MICVO's three mechanisms of action.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000119312525261689/0001193125-25-261689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000119312525261689/pyxs-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer